ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has reported significant advancements in its drug development programs aimed at treating renal and inflammatory diseases. The company's lead drug candidate, VAR 200, a cholesterol efflux mediator, has successfully moved into clinical development and is gearing up for Phase 2 trials. Additionally, ZyVersa's inflammasome ASC inhibitors have demonstrated promise in preclinical studies for treating a variety of inflammatory disorders. ZyVersa is actively seeking strategic partnerships to advance its clinical pipeline and is dedicated to bringing innovative therapies to patients with unmet medical needs.

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has reported significant advancements in its drug development programs aimed at treating renal and inflammatory diseases. The company's lead drug candidate, VAR 200, a cholesterol efflux mediator, has successfully moved into clinical development and is gearing up for Phase 2 trials. Additionally, ZyVersa's inflammasome ASC inhibitors have demonstrated promise in preclinical studies for treating a variety of inflammatory disorders. ZyVersa is actively seeking strategic partnerships to advance its clinical pipeline and is dedicated to bringing innovative therapies to patients with unmet medical needs.